Thus, this review will explore the different generations of CAR-T cells, how they are genetically engineered, and their potential role in immunotherapy; targeting ErbB and MUC1, tumour-associated antigens which are highly expressed by HNSCCs. This evidence concerns the gene MUC1 and neoplasm.